Revvity Stock Gets Reduced EPS Forecast from Zacks Research

Revvity Inc. (NYSE:RVTY) – Equities researchers at Zacks Research dropped their Q1 2028 earnings per share (EPS) estimates for shares of Revvity in a report released on Wednesday, October 28th. Zacks Research analyst Team now expects that the company will post earnings per share of $1.34 for the quarter, down from their prior forecast of $1.35. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Revvity’s current full-year earnings is $5.36 per share. Zacks Research also issued estimates for Revvity’s Q2 2028 earnings at $1.63 EPS, Q3 2028 earnings at $1.62 EPS and FY2028 earnings at $6.51 EPS.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. The company had revenue of $729.69 million during the quarter, compared to analysts’ expectations of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%. The firm’s revenue was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.18 EPS.

Several other research analysts have also recently issued reports on the company. William Blair assumed coverage on Revvity in a research note on Monday, October 5th. They issued an “outperform” rating for the company. KeyCorp upped their target price on Revvity from $125.00 to $165.00 and gave the company an “overweight” rating in a research report on Friday, September 4th. Evercore reiterated an “outperform” rating on shares of Revvity in a report on Wednesday, August 5th. TD Cowen increased their price target on shares of Revvity from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Finally, Wall Street Zen lowered shares of Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. Five research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Revvity currently has an average rating of “Hold” and a consensus price target of $124.43.

Revvity Stock Down 3.3%

Shares of RVTY stock opened at $151.76 on Monday. The stock’s 50-day simple moving average is $145.08 and its 200-day simple moving average is $112.36. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. The firm has a market capitalization of $16.94 billion, a PE ratio of 30.90, a P/E/G ratio of 3.01 and a beta of 1.06. Revvity has a fifty-two week low of $81.22 and a fifty-two week high of $169.06.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Jupiter Topco LLC acquired a new stake in shares of Revvity in the second quarter valued at about $961,017,000. BlackRock Inc. acquired a new position in shares of Revvity during the 2nd quarter worth about $852,070,000. Wellington Management Group LLP raised its position in shares of Revvity by 10,653.8% during the 2nd quarter. Wellington Management Group LLP now owns 865,575 shares of the company’s stock worth $96,304,000 after purchasing an additional 857,526 shares during the last quarter. Primecap Management Co. CA acquired a new position in shares of Revvity during the 2nd quarter worth about $94,921,000. Finally, Bank of America Corp DE purchased a new position in Revvity in the 2nd quarter valued at about $87,116,000. 86.65% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Tajinder S. Vohra sold 7,330 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the sale, the insider directly owned 6,635 shares of the company’s stock, valued at $934,738.80. This trade represents a 52.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Maxwell Krakowiak sold 1,631 shares of the firm’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the sale, the insider directly owned 14,781 shares in the company, valued at approximately $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 9,045 shares of company stock valued at $1,281,439. Insiders own 0.85% of the company’s stock.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 12th. Shareholders of record on Friday, January 22nd will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, January 22nd. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. Revvity’s dividend payout ratio (DPR) is presently 13.33%.

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.